Background: Cystic Fibrosis (CF) is caused by mutations in the CFTR gene, of which over 2000 have 2 been reported to date. Mutations have yet to be analyzed in aggregate to assess their distribution 3 across the tertiary structure of the CFTR protein, an approach that could provide valuable insights 4 into the structure-function relationship of CFTR. In addition, the binding site of Class I correctors 5 (VX-809, VX-661, C18) is not well understood.
Introduction
order to uncover salient trends and provide additional insight into the biochemical, biophysical 1 and/or evolutionary nature of this fatal genetic disease.
2 Accordingly, we employed a structural pharmacogenomics approach 16, 17 to map all exonic 3 mutations and mutant allele frequencies found in these databases of CFTR mutations onto three-4 dimensional structural models of the CFTR protein in both the open-channel 18 and closed-5 channel 19 states. The spatial distribution of the mapped mutations was analyzed to uncover salient 6 trends that may inform on their mechanistic underpinnings. In addition, structural information 7 from the experimentally determined closed-channel conformation 19 was combined with 8 computational docking calculations to predict CFTR residues that contribute to the binding sites of 9 current small molecule therapeutics, mainly Class I correctors: VX-809 (lumacaftor, a component 10 of Orkambi® co-therapy), VX-661 (tezacaftor, the putative successor of lumacaftor) and C18 (an 11 investigational compound).
12
The proposed structural pharmacogenomics approach is shown to yield useful insights into 13 structure-function relationships that underlie CF, and to predict a potential drug binding pocket 14 which may facilitate further stratification of patients based on their mutation-sensitive 'theratype' 15 or responsiveness to certain small molecule therapies 13, 20 . 1 We used a previously described and biochemically validated structural model of full-length CFTR in 2 the open-channel state 18 (i.e. residues 1-1480, including the extensively modeled R-domain), as 3 well as the recent cryo-electron microscopy (cryo-EM)-derived partial/core-structure of CFTR at 4 3.87 Å resolution in the closed-channel state 19 (lacking ~297 CFTR residues, including amino acids 5 1-4, 403-438, 646-843, 884-908, 1173 -1206 and 1437 -1480 PDB ID: 5UAK) , as templates to map 6 exonic CFTR mutations and allele frequencies. The homology model of CFTR in the open-channel 7 state by Mornon et al. (2009) 18 was used, rather than Mornon et al. (2015) 20 , as it is the only 8 structural model of full-length CFTR (i.e. containing all 1480 residues); the latter model lacks the R-9 domain (defined as residues 650-843 in their study; 194 amino acids or ~13% of the protein) and 10 subsequently would omit a substantial proportion of CFTR mutations described in the three CFTR 11 mutation databases (i.e. ABCMdb, CFTR1, CFTR2). Further, use of a homology model was 12 necessary since no experimental structure of CFTR in the open-channel state has been solved at 13 sufficient resolution (i.e. the available low-resolution, ~9 Å structure 21 does not have residue-level 14 detail required for this study). In addition, although of lower resolution than desired for molecular 15 docking approaches, the experimental cryo-EM structure of CFTR in the closed (inactive) 16 conformation was used as a template for molecular docking studies, since it is well-established 17 that 'activating' ligands (e.g. correctors) bind to at least this conformational state 5, 24, 25 . 20 CFTR mutations from the above listed databases were mapped onto the open-and closed-channel 21 structures of CFTR. The ABCMdb, CFTR1 and CFTR2 mutation databases provided a detailed list of 22 1,955, 1,308 and 235 exonic mutations (missense and insertions/deletions, i.e. non-intronic), 23 respectively, which allowed for mutation counts (i.e. number of unique missense or nonsense 24 mutations at a given amino acid position) and allele frequencies to be tabulated and further 25 highlighted on the CFTR protein model using an automated 'paint-by-number' approach. PyMOL 26 (version 1.7) was used to visualize CFTR protein structures. 
CFTR Protein Tertiary Structures

Mapping CFTR Mutations onto the Protein Tertiary Structures
Mutation Density using Average Interatomic Distance Measurements 1
To quantify the probability that the positions of the highest-frequency mutations (i.e. F508del, 2 G542X, G551D, R553X W1282X, N1303K), known to be detrimental to structure and/or function, 3 cluster within the CFTR tertiary structure, we computed the average interatomic distance (AID; 4 mean value of distances between the C α atoms of groups of amino acids) of residues F508, G542, 5 G551, R553 W1282 and N1303, using the atomic coordinates of the full-length CFTR model of the 6 active, open-channel state 18 . This distance was compared to the AID values of 1,000,000 7 randomly-selected six-residue subsets within the CFTR structural model to determine the 8 statistical significance of the spatial clustering observed for the considered mutated positions. 
Identification of Interdomain Interface Residues using Proximity Measurements
11
PyMOL (version 1.7) was used to visualize interdomain interfaces in the full-length homology-12 based structural model of CFTR, mainly NBD1 (residues 381-630), NBD2 (residues 1171-1480) and 13 MSD2 (i.e. intracellular loop 4 or ICL4, residues 1039-1093). Residues at domain-domain interfaces 14 were defined as residues of one domain with at least one atom within a 4 Å distance of any atom 15 in the neighboring domain. Interdomain interface residues for NBD1:NBD2 and NBD1:ICL4 were 16 further annotated by mutation frequency, and residues contained within interdomain interfaces 17 were coloured according to mutation counts.
19
Molecular Docking of Pharmacological Correctors to CFTR
20
VX-809, VX-661 and C18 were docked to the apo form of human CFTR in the closed-channel 21 state 19 (PDB ID: 5UAK) using the CROSSx molecular docking tool from the Ligand Express™ 22 computational suite (Cyclica Inc., Toronto, Canada) 26 . The lowest-energy conformers of the three 23 correctors considered in isolation were modeled, and found to possess up to 20 Å of maximum 24 possible length. Accordingly, a 30x30x30-Å cube centered around residues F374-L375 (amino acids 25 shown to directly interact with the Class I corrector VX-809 27 ) was used to define potential binding 26 site region in the cryo-EM structure of CFTR. The small molecules were then docked to this region 27 using a protocol, which allowed for flexibility of the ligand but kept the side-chains of target 28 protein fixed (i.e. 'rigid' docking). A diverse ensemble of top-scoring sites centered around 1 residues F374-L375 was visually inspected for chemical complementarity between the ligand and 2 target moieties, and a reduced set of structures was docked allowing for flexible side-chains (i.e.
3
'flexible' docking). This protocol produced a total of 9 best docking poses for each of the corrector 4 molecules. Assuming a common recognition mode for the three ligands, poses that align the 5 pharmacophore features shared by the three corrector ligands, denoted here as the common 6 scaffold (Figure S4A) , were selected as the final docking solutions. PyMOL (version 1.7) was used 7 to visualize molecular docking results. Human embryonic kidney (HEK)-293 cells were transfected with CFTR MSD1 constructs (i.e. full-11 length: K381X, and the C-terminus truncation: D373X) using PolyFect Transfection Reagent 12 according to the manufacturer's protocol (Qiagen) and as previously described 28 . HEK-293 cells 13 expressing MSD1 constructs (~35 kDa) were maintained in DMEM (Wisent) supplemented with 14 non-essential amino acids (Life Technologies) and 10% FBS (Wisent) at 37 o C with 5% CO 2 (HEPA 15 incubator, Thermo Electron Corporation) 6,9 . These cells were grown at 37 o C (24 h) ± VX-809 (3 Three CFTR mutation databases: ABCMdb, CFTR1 and CFTR2, were explored to identify CFTR 11 mutations for which the context in the CFTR tertiary structure could be investigated. To this end, 12 only exonic CFTR mutations and their allele frequencies were retrieved from these databases and 13 mapped to their corresponding residue positions in the protein structure. The CFTR structures 14 used for this analysis were a previously described and biochemically validated homology-based (Figure S1A and S1B). 20 ABCMdb curates the scientific literature and aggregates all reports for a given user-defined 21 search regarding mutations in ATP-Binding Cassette (ABC) proteins, CFTR included. Importantly, 22 this database contains validated disease-causing mutations, unvalidated disease-associated 23 mutations, as well as those used to experimentally investigate CFTR structure and function. For 24 example, data for F508 includes the disease mutation: F508del, as well as all possible amino acid 25 substitutions, and therefore contains the greatest number of 'counts' (i.e. twenty) for a single 26 residue position within the CFTR amino acid sequence. Accordingly, this database contains many 27 non-disease-causing mutations. However, such mutations still provide useful insight into the 1 location within the CFTR sequence, which have been biochemically investigated in greater detail.
2
In total, 1,955 exonic CFTR mutations from the ABCMdb were mapped to the CFTR 3 structures ( Figure S2) . Analysis of the structurally mapped mutations reveals that the R-domain, 4 MSD2 and NBD2 are less-well studied compared with MSD1 and NBD1 of CFTR. A somewhat 5 smaller number of mutations were mapped onto the CFTR protein structures from the other two 6 databases: 1,308 mutations from CFTR1 (Figure 1A and 1B) , and 235 mutations from CFTR2 7 (Figure 2A and 2B) . The CFTR1 database represents physician and scientist catalogued mutations, 8 and likely contains the oldest and most comprehensive collection of both validated disease-9 causing and unvalidated disease-associated CFTR mutations. The CFTR2 database contains a 10 smaller collection of CFTR mutations, but the corresponding data are enriched for validated 11 disease-causing variants, as they correlate genetic information to biochemical (in vitro) and clinical 12 (in vivo) parameters and benchmarks (e.g. lung function and pancreatic sufficiency) 7 . Furthermore, 13 the CFTR2 database reports allele frequencies for CF patients mainly in North America and Europe, 14 and thus represents a substantial subset of the worldwide patient population. This dataset is 15 useful for epidemiological studies, and provides a holistic view of the large-scale CFTR mutation 16 landscape.
17
Importantly, the spatial distribution of mapped mutation counts differed between the 18 ABCMdb, CFTR1 and CFTR2 mutation databases. Many mutations from the CFTR1 database 19 mapped to all of the domains (except for the R-domain for which mutations were under-20 represented) ( Figure 1C) . A smaller collection of mapped mutations was contributed by the CFTR2 21 database, which had at least one dominant mutation in each of the first three domains (i.e. MSD1,
22
NBD1 and the R-domain) ( Figure 2C) . Overall however, a greater proportion of known mutations 23 from all three databases were located in the first two N-terminal domains of CFTR (MSD1 and 24 NBD1), suggesting that these two domains play an important role in CFTR structure and function. 
Mutant Allele Frequencies and Disease-Causing Mutations Cluster at Distinct CFTR Interdomain 27
Interfaces 28 In total, 128,354 mutant alleles from the CFTR2 database were mapped onto the tertiary structure 1 of CFTR ( Figure 3A) . Six amino acid positions (F508, G542, G551, R553, W1282, N1303) comprised 2 a majority of the mutant alleles (110,585, ~86% of the total), including 98,735 alleles (~77%) for 3 the F508del mutation alone, and upon further inspection we found that these six positions were 4 spatially co-localized in the tertiary structure of CFTR (Figure 3B and 3C) . This co-localization (AID 5 of 18.75 Å) was found to be statistically significant (p-value ~0.0003) (Figure 3D ; see Methods for 6 details). More specifically, these six residues are part of two distinct interdomain interfaces 7 (NBD1:NBD2 and NBD1:ICL4) which have been previously described as being integral to CFTR 8 structure and function, and accordingly, represents a region of mutation clustering that is over-9 represented in the CF patient population when compared to all of the alleles reported in the 10 CFTR2 database 30-33 .
11
To assess the frequencies of disease-causing mutations at residue positions of the 12 NBD1:NBD2 and NBD1:ICL4 interdomain interfaces, we first identified amino acids that contribute 13 to these interfaces (see Figure S3 and Methods for details). This revealed that the NBD1:NBD2 14 interface was more extensive (94 residues) than the NBD1:ICL4 interface (29 residues) as 15 illustrated in Figure 4 and Table 1 . We then computed the fraction of residues (i.e. ratio) with 16 disease-causing mutations for the full-length CFTR protein to be 0.88 (i.e. 1,308 exonic CFTR 17 mutations among 1,480 total residues, as reported in the CFTR1 database). The corresponding 18 fractions for the NBD1:NBD2 and NBD1:ICL4 interfaces were 1.06 (i.e. 88 mutations among 94 19 residues, p>0.05) and 1.60 (i.e. 41 mutations among 29 residues, p<0.05), respectively (Table 1) . 20 These data indicate that these two interdomain interfaces have, on average, a larger fraction of 21 mutated residues than full-length CFTR. Importantly, NBD1:ICL4 was found to harbour a 22 statistically significant cluster of mutations, in agreement with the current paradigm that this 23 region plays a crucial role for competent CFTR biosynthesis, stability and activity, as demonstrated 24 by the major mutation (F508del) which is located at this interface 32, 33 . 
Prediction of Corrector-sensitive CFTR Residues 27
The recently determined Cryo-EM structure of CFTR represents an unprecedented opportunity for 1 identifying the binding sites of corrector ligands, as this structure represents the closed-channel 2 conformation of the protein to which such ligands are believed to bind. Identifying the long sought 3 binding site, or sites, of such ligands should help gain insight into the mechanism-of-action of 4 these molecules and allow for patient stratification based on their mutation-sensitive 'theratype'.
5
To this end, we consider the Class I corrector ligands VX-809, VX-661 and C18, which share 6 a common scaffold (pharmacophore), but also display some differences (Figure S4A ). Previous 7 studies have shown that VX-809 stabilizes the MSD1 domain of CFTR 27, 28, 34 . This stabilizing effect 8 was abolished in MSD1 constructs that lacked the C-terminal segment comprising residues 374-9 380 27 . In addition, the deletion of only residues 371-375 from full-length CFTR produced a severe 10 folding defect that could not be corrected by VX-809 27 . It therefore seems of interest to explore 11 this region of CFTR for corrector binding sites. This choice was further confirmed by 12 immunoblotting experiments carried out in this study. These experiments show that deletion of 13 residues 373-380 abrogates corrector-mediated increase in MSD1 abundance, a common measure 14 of the presence of folded protein, for all three Class I correctors (VX-809, VX-661 and C18) ( Figure   15 5A and 5B). This observation suggests that all three ligands interacted with the C-terminal region 16 of MSD1, in agreement with previous findings on VX-809 alone.
17
Docking calculations for all three ligands were hence carried out in the vicinity of residues 18 F374 and L375 using the bounded volume described in the Methods and illustrated in Figure 5C . 19 Assuming a similar mode of action for the three ligands, we favored docking poses in which the 20 common scaffold of these molecules was closely aligned. The docking results, consisting of a top- Table S1 ). The majority of the 24 residues making contact with the ligands are from MSD1 (i.e. lasso motif, ICL1 and C-term), a few 25 are from the N-terminus of NBD1, and only a couple of residues at most from MSD2 (i.e. ICL4). The 26 side-chain of one residue in particular, K166 (ICL1), appears to play an important role in corrector 27 recognition. It was positioned closest (~4.0 Å) to the plane of the common scaffold in the top-28 scoring CFTR-corrector complexes, allowing the ε-amino group of the lysine side-chain to possibly 1 coordinate with the aromatic ring or carbonyl oxygen of this scaffold of each corrector so as to 2 form cation-π interactions or H-bonds, respectively (Figure S4B) . It is noteworthy that the ligands 3 make no contact with the side-chain of F374 and minimal contact with the side-chain of L375, 4 consistent with the finding that mutations of these residues to Alanine has little effect on the 5 potency of VX-809 27 . In this study, the known repertoire of exonic mutations and mutant allele frequencies in CFTR, 9 compiled in three public databases, was mapped onto the three-dimensional structural models of 10 the CFTR protein. Analysis of the spatial distribution of the mapped mutations revealed that 11 disease-causing mutations tend to occur more frequently in certain regions of the CFTR structure, 12 which likely play a strategic role in conferring the thermodynamic and dynamic properties 13 required for protein function.
14 Mapping CFTR mutations from the ABCMdb, which includes validated disease-causing 15 mutations, unvalidated disease-associated mutations, and those of experimental origin, showed 16 that the N-terminal domains of CFTR (MSD1 and NBD1) have been more extensively probed by 17 mutation studies. The greater focus on the N-terminal domains may be due to the occurrence in 18 these domains of two relatively more common disease-causing mutations, R117H and F508del, 19 and perhaps also to the increased influence that residues in the N-terminal half of this large 20 polypeptide may have on proper folding of the full CFTR protein.
21
In contrast, mapping disease-causing mutations only from the CFTR1 and CFTR2 databases 22 to the CFTR protein structures revealed that, for CFTR1, such mutations are found in all domains 23 across the structure, while for CFTR2, where the mutations data is more limited but enriched for 24 validated variants, MSD1 and NBD1 contain the greatest abundance of mutated residues. Further, 25 analysis of the spatial distribution of amino acid positions of the most frequent mutant alleles 26 derived from the CFTR2 database, revealed a statistically significant cluster in the tertiary protein 27 structure containing six of the most common disease-causing mutations; this spatial distribution 1 was not completely apparent in the primary sequence. We speculate that selection pressures (e.g. 2 environmental stresses) played a role in giving rise to this cluster, possibly supporting the 3 heterozygote advantage hypothesis [35] [36] [37] [38] . The latter suggests that carriers (i.e. heterozygotes) of a 4 mutant CFTR allele are thought to have had a survival advantage compared to individuals with 5 wild-type, and thus pressure-susceptible alleles; the leading hypotheses, although controversial 6 among CF researchers, propose a survival advantage against cholera, typhoid fever and/or 7 tuberculosis 35-38 . 8 In addition, we found that disease-causing mutations were clustered at two distinct 9 interdomain interfaces, NBD1:NBD2 and NBD1:ICL4, with the cluster at the latter interface being 10 statistically significant (p<0.05). This observation confirms that these regions are fragile 'linchpins', 11 essential for intramolecular communication and facilitating conformational changes required for 12 CFTR function, and further, that mutation of individual residues within these interfaces is sufficient 13 to destabilize and/or hamper proper tertiary assembly of functionally competent states of the 14 protein 29,30 . This is in agreement with previous studies ,which showed that residues buried within is based on the canonical scaffold, which is well-represented in the structurally-characterized Protein Data Bank (PDB). This model represents the ATP-bound state of CFTR, which correlates 1 with a large set of structural homologues in the PDB (i.e. ATP-bound, non-mammalian ABC 2 transporters) and is in agreement with several biochemical studies, further supporting its 3 validity 18 .
4
In the last part of our study, we investigated the putative binding site of three Class I 5 correctors molecules, VX-809, VX-661 and C18. We confirmed experimentally that all three ligands 6 stabilized MSD1 of CFTR, requiring the C-terminal segment of this domain to elicit their corrector 7 action, as reported for VX-809 in other studies 27, 28, 34 . The three ligands were then computationally 8 docked onto a 30-Å 3 region centered at the C-terminal region of MSD1 (i.e. residues F374-L375) in 9 the cryo-EM structure of CFTR, and poses which demonstrated alignment of the pharmacophore 10 (i.e. common scaffold) of these three small molecules suggested the most plausible binding 11 pocket. This enabled the identification of a sizable binding pocket with least 12 residues of the 12 CFTR protein (a sufficient number for ligands of these molecular weights: i.e. ~450-520 Da), many 13 of which were in MSD1, engaging in interactions with the bound ligands (Table S1 ). Our findings 14 that the identified corrector binding pocket comprises residues from different domains (i.e. lasso 15 motif, ICL1 and C-term of MSD1, N-terminus of NBD1, and ICL4 of MSD2; Table S1 ) further 16 elaborate on previous in silico docking studies, which propose that a composite, multi-domain 17 pocket comprised of residues within the NBD1:ICL4 interface (near the major mutation: F508del) 18 is likely to accommodate VX-809 24,25 .
19
More specifically, we found that the three non-pharmacophore hydroxyl groups of VX-661, 20 which are not featured in the investigational and first-generation corrector molecules: C18 and 21 VX-809, respectively (Figure S4A) , formed H-bonds with residues E54, W57 and K163 in the 22 predicted pocket (Figure S4B) , possibly explaining the in vitro effectiveness of VX-661 over these 23 other correctors. Furthermore, binding poses for all three correctors position the pharmacophore 24 in a groove comprising residues K166, Y380, T382, R1066 and Q1071, and interacting more closely 25 with K166. In the complex with VX-661, the positively charged epsilon amino group of K166 was 26 appropriately positioned towards the aromatic benzodioxole group to form a potential cation-π in an appropriate geometry for an H-bond with the corrector's carbonyl oxygen of the 1 pharmacophore (data not shown). These different options for the K166 side-chain to form 2 stabilizing interactions with different ligands or possibly with the same ligand, support the 3 predicted involvement of this residue in corrector binding. Furthermore, our future studies will 4 investigate the role of K166 in coordination and subsequent binding of these Class I correctors 5 using a site-directed mutagenesis approach. 6 Finally, it is noteworthy that disease-causing mutations have been reported for several 7 residues in the predicted binding pocket (e.g. R1066C/S/H/L; see Table S1 ). It is therefore possible 8 that the Class I correctors analyzed here may repair structural defects caused by these variants 9 (locally in this pocket and globally throughout CFTR protein), and potentially become 10 therapeutically relevant for CF patients bearing these mutations. Taken together, these data 11 suggest that the current CF co-therapy (i.e. Orkambi®, but mainly lumacaftor) may benefit this 12 patient subpopulation. Furthermore, it is clear that additional investigations using mutational and 13 biophysical analyses are needed to confirm the predicted binding pocket and the proposed 14 contributions of various CFTR residues therein to the binding of the three Class I correctors. Cell 169(1) , 85-95 (2017) . Sci. 72(7) , 1377-403 (2015) . Nat. Rev. Genet. 16, 45-56 (2015) . Biol 9(7) , 444-54 (2013) . Cell 24, 3016-24 (2013) . 23(7) , 1362-9 (2015) . Chem Int Ed Engl. 44(28) , 4400-4 (2005) . Sci USA 96(17), 9459-64 (1999) . binding mode of VX-661, captured in the putative corrector binding pocket of the cryo-EM-derived 8 partial structure of CFTR in the closed-channel (inactive) state, is shown in the inset (pink, lasso 9 motif; yellow, ICL4 of MSD2; cyan, NBD1; light blue, ICL1 of MSD1; dark gray, K166; magenta, VX-10 661; dashed yellow line, predicted cation-π interaction). A two-dimensional representation of the 11 predicted binding mode of the example Class I corrector, VX-661, in the putative corrector binding 12 pocket (corresponding to the inset) is also shown, as generated using the PoseView tool from the 13 ZBH ProteinsPlus webserver (proteinsplus.zbh.uni-hamburg.de). Supplementary Table Captions   18   19   Table S1 : CFTR residues predicted to interact with Class I correctors VX-809, VX-661 and C18. 20 List of residues (subdomain, domain) predicted to be within 5 Å of each respective small molecule 21 corrector following molecular docking studies. Residues in italics are common among the three 22 compounds, and the residue in bold italics (i.e. K166) is found ~4.0 Å of the common scaffold or 23 'pharmacophore' of each corrector. Residues bearing disease-associated missense mutations, as 24 reported in the CFTR1 database, are labelled with an asterisk. 
